ITC Refuses To OK Amgen, Roche Anemia Drug Deal

Law360, New York (November 10, 2011, 6:40 PM EST) -- The U.S. International Trade Commission on Wednesday finally dropped its investigation into a patent fight between Amgen Inc. and Roche Holding Ltd. over an anemia drug after their 2009 settlement, but refused to approve what it said was an unusual consent order requested by the parties.

In an opinion issued Wednesday, the ITC said the proposed consent order blocking Roche from importing the anemia drug Mircera into the U.S. until 2014 — as laid out in the Dec. 2009 settlement — included language "not routinely seen...
To view the full article, register now.